NEW YORK, Nov. 6, 2017 /PRNewswire/ -- If you want a Stock Review on CARA, CATB, CERS, or GNCA then come over to http://dailystocktracker.com/register/and sign up for your free customized report. On Friday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading session up 0.74%; the Dow Jones Industrial Average edged 0.10% higher; and the S&P 500 was up 0.31%. US
Stamford, Connecticut headquartered Cara Therapeutics Inc.'s stock finished Friday's session 0.90% higher at $12.33. A total volume of 1.92 million shares was traded, which was above its three months average volume of 917.28 thousand. The Company's shares have advanced 109.34% in the last twelve months and 32.72% on an YTD basis. The stock is trading below its 50-day moving averages by 6.43%. Furthermore, shares of Cara Therapeutics, which focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the US, have a Relative Strength Index (RSI) of 41.72. Free research report on CARA is available at:
Shares in Cambridge, Massachusetts-based Catabasis Pharmaceuticals Inc. ended at $1.99, up 8.15% from the last trading session. The stock recorded a trading volume of 639,460 shares. The Company's shares have gained 53.08% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 1.75% and 23.46%, respectively. Moreover, shares of Catabasis Pharma, which focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted linker drug discovery platform in the US, have an RSI of 45.39. The complimentary research report on CATB can be downloaded at:
Concord, California headquartered Cerus Corp.'s stock ended last Friday's session 22.22% higher at $3.52 with a total trading volume of 3.68 million shares, which was above its three months average volume of 854.51 thousand shares. The Company's shares have advanced 15.41% in the past month and 40.52% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 27.80% and 10.48%, respectively. Additionally, shares of Cerus, which focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety, have an RSI of 72.99. Visit us today and access our complete research report on CERS at:
On Friday, shares in Cambridge, Massachusetts headquartered Genocea Biosciences Inc. recorded a trading volume of 869,435 shares. The stock finished the day 4.55% lower at $1.05. The stock is trading below its 50-day moving averages by 65.41%. Furthermore, shares of Genocea Biosciences, which engages in developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer, have an RSI of 18.62. Get free access to your research report on GNCA at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACTFor any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/technical-insights-on-biotech-stocks----cara-therapeutics-catabasis-pharma-cerus-and-genocea-biosciences-300549882.html
Subscribe to our Free Newsletters!
Drug abuse is a negative social trend that pushes youth to drug addiction in the pretext of getting ...
Proper understanding of waste collection, segregation and management is required to reduce the ...
Leukoplakia refers to a painless, raised white patch in the mouth that does not go away on rubbing, ...View All